Description
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs.
The Company is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases.
The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases.
The Company is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. It is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.
